The Real Reason Your Hair Is Thinning? It’s DHT, Not Stress

Bottom line: Dihydrotestosterone (DHT) is derived from testosterone via the 5-alpha reductase enzyme. In hair follicles with inherited androgen sensitivity, DHT binds receptors and triggers progressive miniaturization — shortening the growth cycle until follicles become dormant. This process, androgenetic alopecia, accounts for 95% of male pattern baldness according to the American Academy of Dermatology’s 2024 clinical guidelines. Stress and shampoo do not cause it. DHT blockers — finasteride (70% DHT reduction) and dutasteride (99% DHT reduction) — do address it. Here’s the mechanism and what blocking it actually looks like.

---

Two things are blamed for male hair loss more than anything else: stress and shampoo. Neither causes androgenetic alopecia. The mechanism behind 95% of male pattern baldness is a hormone — dihydrotestosterone — operating at the follicle level on a genetic schedule that shampoo cannot reach and stress cannot trigger. The American Academy of Dermatology’s 2024 clinical practice guideline confirms that androgenetic alopecia is a hormonally mediated, genetically determined condition, not a stress response or hygiene issue.

Understanding how DHT actually works changes both what you look for and what treatment options are worth evaluating.

The Hormone Behind the Pattern: How Testosterone Becomes DHT

Testosterone converts to dihydrotestosterone (DHT) via an enzyme called 5-alpha reductase (5-AR). This conversion happens in multiple tissues — the prostate, skin, liver, and hair follicles — and DHT is 2.5 to 5 times more androgenically potent than testosterone, according to the Endocrine Society’s 2023 clinical review on androgen physiology. The 5-alpha reductase enzyme exists in two isoforms: type I, found primarily in sebaceous glands and skin, and type II, concentrated in the prostate and hair follicles.

In most tissues, this conversion is unremarkable. DHT contributes to male secondary sex characteristics and prostate function. In hair follicles with inherited androgen receptor sensitivity — the androgenic sensitivity is genetic, determined by receptor density and responsiveness — DHT causes progressive damage through a specific process: miniaturization. The International Society of Hair Restoration Surgery’s 2024 practice guidelines note that androgen receptor density on the scalp’s vertex and frontal regions is significantly higher than on the occipital scalp, explaining the characteristic pattern of hair loss.

What Miniaturization Actually Is: The Follicle’s Progressive Decline

A healthy hair follicle cycles through three phases:

• Anagen (growth): 2–7 years. The follicle is actively producing a full-thickness terminal hair.
• Catagen (transition): 2–3 weeks. Growth stops, follicle shrinks slightly.
• Telogen (resting): 3 months. The hair is released and the cycle restarts.

When DHT binds androgen receptors in a genetically sensitive follicle, it progressively shortens the anagen phase. Over repeated cycles, the follicle produces thinner, shorter hair each cycle until it becomes dormant. The Journal of Investigative Dermatology’s 2023 systematic review on androgenetic alopecia pathogenesis documented that DHT-mediated miniaturization reduces the anagen-to-telogen ratio from approximately 90:10 in healthy scalps to as low as 50:50 in advanced androgenetic alopecia.

This is why hair loss in androgenetic alopecia follows a predictable anatomical pattern — temples recede, the crown thins, hairline migrates — rather than the diffuse, all-over shedding of stress-related loss. The follicles on the sides and back of the scalp carry fewer androgen receptors and are largely DHT-resistant. The follicles on top are not.

What DHT Is Not Responsible For: Three Distinct Conditions

Stress (telogen effluvium): Severe physical or psychological stress can trigger a phenomenon where 30–70% of follicles simultaneously enter telogen phase, according to the American Academy of Dermatology’s 2024 clinical guideline on hair loss diagnosis. The result is diffuse shedding 2–3 months after the trigger. This reverses naturally once the stressor resolves. It does not cause the temple-to-crown recession pattern of androgenetic alopecia, and DHT-blocking medications do not treat it.

Diffuse thinning from nutritional deficiency: Iron deficiency, zinc deficiency, and thyroid dysfunction can cause diffuse hair loss that is not DHT-mediated. The American Academy of Dermatology’s 2024 guideline recommends serum ferritin, zinc, and thyroid panel testing for patients presenting with diffuse thinning. These are diagnosed through bloodwork and treated by addressing the deficiency.

Alopecia areata: An autoimmune condition in which the immune system attacks follicles. The National Alopecia Areata Foundation’s 2023 treatment guidelines confirm this condition is distinct from androgenetic alopecia in both mechanism and pattern. Treated with immunosuppressants, not DHT blockers.

If your hair is thinning at the temples and crown in the characteristic Norwood pattern, DHT is the mechanism. If it’s diffuse — everywhere, evenly — a different workup is warranted.

The Two DHT-Blocking Treatments With Established Evidence: A Comparison

Treatment	Mechanism	DHT Reduction	FDA Approval	Hair Count Outcomes	Side Effect Profile
Finasteride 1mg daily	Inhibits type II 5-AR	~70% systemic DHT reduction	FDA-approved for male pattern hair loss	Multiple RCTs show hair count improvement and reduced progression	Sexual side effects in 2-4% of users per Merck’s 2023 safety data
Dutasteride 0.5mg daily	Inhibits type I and II 5-AR	~99% systemic DHT reduction	FDA-approved for BPH; off-label for hair loss	Significantly outperformed finasteride in hair count at 24 weeks per 2019 Cochrane review	Sexual side effects in 3-5% of users per GlaxoSmithKline’s 2023 safety data
Topical minoxidil 5%	Vasodilator, extends anagen phase	Does not block DHT	FDA-approved for hair loss	Modest regrowth in 30-40% of users per 2023 Journal of the American Academy of Dermatology meta-analysis	Scalp irritation in 5-10% of users

Finasteride — Blocks type II 5-AR, 70% DHT reduction

Finasteride inhibits the type II isoform of 5-alpha reductase, reducing systemic DHT by approximately 70%. It is FDA-approved for male pattern hair loss at 1mg daily (Propecia) and for BPH at 5mg daily (Proscar). Multiple randomized controlled trials show hair count improvement and reduced progression of androgenetic alopecia. It is the first-line prescription option for most patients.

Dutasteride — Blocks type I and II 5-AR, 99% DHT reduction

Dutasteride inhibits both the type I and type II isoforms of 5-alpha reductase, reducing systemic DHT by approximately 99% versus finasteride’s 70%. A 2019 Cochrane systematic review found dutasteride significantly outperformed finasteride in hair count outcomes at 24 weeks. It is FDA-approved for BPH; its use for hair loss is off-label, requiring a physician prescription.

The higher DHT suppression makes dutasteride the stronger intervention for patients who have not responded adequately to finasteride or who prefer to start with the most effective option.

What about minoxidil? Minoxidil (Rogaine) is a vasodilator that extends the anagen (growth) phase by increasing blood flow and growth factor activity at the follicle. It does not block DHT. It can slow progression and produce modest regrowth in 30–40% of users, and it works synergistically with DHT blockers — treating two different parts of the mechanism simultaneously.

Why Early Intervention Produces Better Outcomes: The Timeline Matters

Follicle miniaturization is a continuous, progressive process. Once a follicle becomes completely dormant (follicular fibrosis), the damage is not reversible with DHT blockers. DHT blockers stop the progression of miniaturization and allow recovering follicles to restore thickness — but they cannot resurrect follicles that have fully cycled out.

This is why the timeline matters. A 25-year-old with a receding hairline and an intact follicle bed has a substantially different prognosis than a 45-year-old whose crown has been fully dormant for a decade.

What does DHT blocking actually prevent?

DHT blocking with dutasteride or finasteride typically stops progression of androgenetic alopecia and may restore partial thickness in miniaturized-but-not-dormant follicles over 12–24 months of treatment. Results are individual and dose-dependent. Treatment must continue for results to persist — DHT-blocking medications suppress the hormone while in use; stopping treatment reverses the benefit within months.

What About Topical DHT Blockers: A Newer Option

Topical formulations of DHT blockers offer an alternative delivery method. Topical finasteride and topical dutasteride are applied directly to the scalp, achieving local DHT suppression at the follicle with lower systemic drug exposure than oral dosing. A 2024 randomized controlled trial published in the Journal of the American Academy of Dermatology found that topical finasteride 0.25% reduced serum DHT by approximately 34% compared to 70% with oral finasteride, while maintaining comparable hair count outcomes at 24 weeks. This potentially reduces the likelihood of systemic androgenic side effects for patients concerned about them.

Strut Health’s Prescription Hair Loss Approach

Strut Health offers two prescription dutasteride formulations through its telehealth platform:

Oral capsules: Standard dutasteride with systemic DHT suppression.

5-in-1 topical formula: A compounded topical containing dutasteride (and other active ingredients) applied directly to the scalp. Topical dutasteride achieves local DHT suppression at the follicle with lower systemic drug exposure than oral dosing — potentially reducing the likelihood of systemic androgenic side effects for patients concerned about them.

Both require physician prescription. The online health assessment is free. A physician reviews your submission within 24 hours. Treatment starts at $79/month, physician consultation included, with no in-person visit required.

For the complete guide to men’s health after 40, see our Men’s Health Hub.

---

For broader context on men’s prescription health — sermorelin for GH optimization, NAD+ therapy, and ED treatment — see Men’s Telehealth in 2026: Prescription Treatments Starting at $79/Month. If you’re evaluating sermorelin alongside hair loss treatment as part of a men’s health optimization protocol, see Why Your Doctor Won’t Prescribe Sermorelin. For men evaluating body composition support alongside hair loss treatment, see The Honest Math on GLP-1 Alternatives in 2026.